乐观
$2.24
情景价格
$0.073
+0.009 (+11.79%)收盘时
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
Given the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

China SXT Pharmaceuticals Closes $12 Million Direct Offering

China SXT Pharmaceuticals Announces Direct Offering of 8 Million Shares

China SXT Pharmaceuticals Closes $9 Million Direct Offering

China SXT Pharmaceuticals Secures $9M Direct Offering

DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.

$GNPX October 2024 and October 2025. Two Octobers in a row produced strong rallies, and anyone who has followed GNPX closely would recognize that. In 2024 the month finished up about 522%...... The sample is two years, both moves were tied to a thin float, and the current float is even smaller than it was over the last two years, so it may be worth watching for a trade. For that reason, I mentioned GNPX as a potential $SXTC type mover. Let's see what this month brings.
展开
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。